Special to Ophthalmology Times®
Autologous serum eye drops (ASEDs) have become a mainstay of therapy for certain categories of patients with dry eye and those with underlying immunologic disease or poor epithelial healing.
The logistics of prescribing ASEDs have changed dramatically in the past few years, making their use far more convenient for patients and physicians alike. Many still hold on to myths and misconceptions about ASEDs that are no longer true.
About the author
Joseph Tauber, MD
e: jt@taubereye.com
Dr Tauber is fellowship trained in both cornea and uveitis. He is in private practice at the Tauber Eye Center in Kansas City, Missouri, and serves as the medical director for Saving Sight Eye Bank, where Vital Tears are produced. He has no financial interest in Vital Tears.
References
Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467-1474.
Garcia-Martin E, Pernia-Lopez S, Jimenez RMM, et al. The use of autologous serum eye drops for the treatment of ocular surface disorders. Eur J Hosp Pharm. 2019;26(6):314-317.
Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):619-626.
Jirsova K, Brejchova K, Krabcova I, et al. The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment. Curr Eye Res. 2014;39(1):21-30.
Dalmon CA, Chandra NS, Jeng BH. Use of autologous serum eyedrops for the treatment of ocular surface disease: first US experience in a large population as an insurance-covered benefit. Arch Ophthalmol. 2012;130(12):1612-1613.
Ali TK, Gibbons A, Cartes C, et al. Use of autologous serum tears for the treatment of ocular surface disease from patients with systemic autoimmune diseases. Am J Ophthalmol. 2018;189:65-70.
Jeng BH, Dupps WJ Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. Cornea. 2009;28(10):1104-1108.
Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106(10):1984-1989.
Sharma N, Kaur M, Agarwal T, et al. Treatment of acute ocular chemical burns. Surv Ophthalmol. 2018;63(2):214-235.
Behrens A, Doyle JJ, Stern L, et al; Dysfunctional tear syndrome study group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900-907.
Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575-628.
Starr CE, Gupta PK, Farid M, et al; ASCRS Cornea Clinical Committee. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019;45;669-684.
